AbbVie acquires Syndesi for $1bn
AbbVie has acquired Syndesi Therapeutics from Novo Holdings for up to $1 billion.
1 March 2022•3 mins read
AbbVie has acquired Syndesi Therapeutics from Novo Holdings for up to $1 billion.
Walter Capital Partners takes significant stake in Quebec educational games maker Passe-Temps
13 hours ago · 1 min read
Truelink Capital’s GES buys CSG Creative from National Trade Productions
13 hours ago · 2 mins read
MPE Partners’ Intermatic adds outdoor lighting-control products maker Sun-Tech
13 hours ago · 2 mins read
Velocity Capital Management backs founder Griffin Haddrill with stake in LV8, Mirage
13 hours ago · 1 min read
Aterian’s Outlook Group completes acquisition of Graham-backed ABX’s Pewaukee packaging facility
13 hours ago · 1 min read
FPE Capital’s NoBlue2 adds PeopleWalking’s Spanish NetSuite business in Europe push
14 hours ago · 1 min read
PE targets identity security as AI transforms threats: 6 deals
15 hours ago · 3 mins read
